## Abstract Retroperitoneal sarcoma, regardless of the histopathologic grade of malignancy, has a high incidence of local recurrence that is usually fatal. Surgical resection is mandatory and resectability may be improved by a midline transabdominal approach. However, even with total tumor excision
Retroperitoneal sarcomas: Combined-modality treatment approaches
β Scribed by Chandrajit P. Raut; Peter W.T. Pisters
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 142 KB
- Volume
- 94
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
β¦ Synopsis
Retroperitoneal sarcomas (RPS) are rare tumors, accounting for approximately 15% of soft tissue sarcomas. Surgical resection of localized tumors with gross and microscopically negative margins remains the standard of care. However, because RPS are frequently large and locally advanced, resections are often incomplete, resulting in local recurrence. Investigators are evaluating combined-modality therapies to improve local control and disease-specific survival. This review outlines current concepts and evolving treatment strategies in the diagnosis, staging, and management of RPS.
π SIMILAR VOLUMES
## Abstract ## Background. Primary bone sarcomas arising in osseous structures of the head and neck are rare. These tumors are often incompletely resected and treated with radiotherapy for local control. ## Methods. We report a case of a 9βyearβold girl with a maxillary Ewing's sarcoma. This pat
## Abstract ## Background and Objectives Photodynamic therapy causes direct cytotoxicity to malignant cells within a tumor. Photodynamic therapy (PDT) can also have both direct and indirect effects upon various nonβmalignant components of the tumor microenvironment. This action can lead to PDTβmed
Children diagnosed with rhabdomyosarcoma at the Tata Memorial Hospital during the period January 1986December 1988 were studied. All were treated with combination chemotherapy incorporating vincristine, Adriamycin, and cyclophosphamide given sequentially in repeated cycles over 18 months, along with